Chemistry:EGX-B

From HandWiki

EGX-B is a serotonin 5-HT2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders.[1][2][3] It acts as a agonist of the serotonin 5-HT2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT2A receptor over the serotonin 5-HT2B receptor, is much more potent as a serotonin 5-HT2A receptor agonist than psilocin, and produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents.[3][4] The drug is being developed by atai Life Sciences and EntheogeniX Biosciences.[1][2] As of December 2023, it is in the preclinical research stage of development.[1][2]

See also

References

  1. ↑ 1.0 1.1 1.2 "EGX B". 8 December 2023. https://adisinsight.springer.com/drugs/800076205. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on EGX-B with Synapse". 25 January 2025. https://synapse.patsnap.com/drug/7baff5a71d1d47598cf0af1ce30c9aac. 
  3. ↑ 3.0 3.1 "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P362. Discovery of Novel 5-HT2A Receptor Agonists With Psychedelic Drug-Like in Vitro and in Vivo Pharmacological Activity and Therapeutic Potential for Treatment-Resistant Depression". Neuropsychopharmacology 48 (Suppl 1): 211–354 (275–275). December 2023. doi:10.1038/s41386-023-01756-4. PMID 38040810. PMC 10729596. https://ir.atai.life/static-files/d589b5ff-b604-4321-925e-3f01fb7f7911. 
  4. ↑ "Data from our novel EGX series shows translational antidepressant-like effects, similar to those seen with psilocybin". atai Life Sciences. 21 November 2023. https://www.linkedin.com/pulse/data-from-our-novel-egx-series-shows-translational-fo1re/. 





Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:EGX-B&oldid=4032719"